2017 IPO
Quanterix Stock
Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Sign up today and learn more about Quanterix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Quanterix Stock
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.
Funding History
| August 2008 | $15.0M |
|---|---|
| October 2010 | $2.5M |
| August 2011 | $6.0M |
| March 2012 | $2.0M |
| November 2012 | $18.5M |
| March 2016 | $46.0M |
Management
Chief Medical Officer
Andreas Jeromin
Senior Director, Manufacturing Operations
James Drummey
Senior Director, Sales & Marketing
Julien Bradley
VP, Product Development
David H. Wilson
Scientific Founder & Board Director
David R. Walt
Chairman & CEO
Kevin Hrusovsky
CTO & VP, Research
David Duffy, Ph.D.
CFO
Ernest Orticerio
Director
Paul M. Meister
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
